Black Friday is Now! Don’t miss out on up to 60% OFF InvestingProCLAIM SALE

UK agrees to licence three-parent IVF babies to prevent disease

Published 15/12/2016, 19:52
© Reuters.  UK agrees to licence three-parent IVF babies to prevent disease

By Kate Kelland

LONDON (Reuters) - Britain on Thursday became the first country to formally licence an in-vitro fertilisation (IVF) treatment designed to create babies from three people.

Critics of the treatment say it is a dangerous step that will lead to the creation of genetically modified "designer babies".

In a long-awaited decision, Britain's Human Fertilisation and Embryology Authority (HFEA) gave the final go-ahead for the treatment known as mitochondrial transfer, which doctors say could help prevent incurable inherited diseases.

Britain's parliament voted last year to change the law to allow the treatments if and when they were ready for licensing. This latest HFEA decision means the first babies created by the technique in Britain could be born in 2017.

The government's chief scientific adviser, Mark Walport, praised the HFEA'S decision as a "careful and considered" assessment which put Britain at the forefront of medical advances.

The technique involves intervening in the fertilisation process to remove mitochondria, which act as tiny energy-generating batteries inside cells, and which, if faulty, can cause fatal heart problems, liver failure, brain disorders, blindness and muscular dystrophy.

The treatment is designed to help families with mitochondrial diseases - incurable conditions passed down the maternal line that affect around one in 6,500 children worldwide.

"Mitochondrial donation offers a real opportunity to cure a class of potentially devastating inherited conditions and will bring hope to hundreds of affected families in the UK," said Dagan Wells, a professor at Oxford University's biomedical research centre and one of many experts welcoming the decision.

The treatment is known as "three-parent" IVF because the babies, born from genetically modified embryos, would have DNA from a mother, a father and from a female donor.

Jeremy Farrar, director of the Wellcome Trust global health charity, said it was a "landmark day for people living with mitochondrial disease".

Research teams around the world have tested and trialled the techniques in a series of pre-clinical experiments, but as yet they have not been used to treat patients in Britain.

The world's first and so-far only known mitochondrial transfer baby was born earlier this year after U.S. doctors working at a clinic in Mexico helped a Jordanian couple conceive using the new three-way treatment.

David King of the campaign group Human Genetics Alert said the HFEA's move would allow use of a "dangerous and medically unnecessary technology".

"This decision opens the door to the world of GM designer babies," he said in an emailed statement.

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.